Journal of Current Glaucoma Practice

Register      Login

VOLUME 6 , ISSUE 2 ( May-August, 2012 ) > List of Articles

PERSPECTIVE

The Anti-VEGF Epidemic: What are the Implications for Glaucoma Services?

Simon E Skalicky, Colin I Clement

Keywords : Bevacizumab, Glaucoma, VEGF

Citation Information : E Skalicky S, Clement CI. The Anti-VEGF Epidemic: What are the Implications for Glaucoma Services?. J Curr Glaucoma Pract 2012; 6 (2):55-57.

DOI: 10.5005/jp-journals-10008-1106

License: CC BY-NC 4.0

Published Online: 01-08-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

The early reports on intraocular bevacizumab injections talked about a transient predictable probably volume-related rise in intraocular pressure (IOP). As the usage of the drug increased across the globe, sustained IOP elevation was noted. This article provides an insightly into the causes of IOP spikes and its impact on glaucoma practice.


PDF Share
  1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 Oct;355(14):1419-1431.
  2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 2006 Oct 6;355(14):1432-1444.
  3. Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma. Clin Ophthalmol 2011;5:797-800.
  4. Bahar I, Yeung SN, Sella R, Slomovic A. Anterior segment uses of bevacizumab. Curr Opin Ophthalmol 2012 Jul 23(4):303-316.
  5. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: An unreported complication. Eye (Lond) 2007 Dec;21(12):1541.
  6. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009 May-Jun;40(3):293-295.
  7. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008 Jul;246(7):955-958.
  8. Skalicky SE, Ho I, Agar A, Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 2012 Jul;43(4):328-334.
  9. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011 Aug;95(8):1111-114.
  10. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010 Feb;26(1):105-110.
  11. Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, Geyer O. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012 Oct;250(10):1435-1440.
  12. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012 Feb;119(2):321-326.
  13. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 2010 Sep;19(7):437-441.
  14. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008 Jul-Aug;28(7):996-1001.
  15. Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: Effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011 Feb;52(2):1023-1034.
  16. Health Professionals [Internet]. Australian medicare benefits schedule. Available at: http://www.medicare australia.gov.au.
  17. Australian Bureau of Statistics [Internet]. News Releases. Available at: http://www.abs.gov.au.
  18. Australian pharmaceuticals benefits scheme [Internet]. News updates. Available at: http://www.pbs.gov.au.
  19. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators. Ranibizumab for macular edema after branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 2010 Jun;117(6):1102-1112.
  20. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, et al; Diabetic retinopathy clinical research network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010 Jun;117(6):1064-1077.
  21. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: A randomized control trial. J Glaucoma 2009 Oct-Nov;18(8):632-637.
  22. Kotecha A, Spratt A, Ogunbowale L, dell'Omo R, Kulkarni A, Bunce C, Franks WA. Intravitreal bevacizumab in refractory neovascular glaucoma: A prospective, observational case series. Arch Ophthalmol 2011 Feb;129(2):145-150.
  23. Chua BE, Nguyen DQ, Qin Q, Ruddle JB, Wells AP, Niyadurupola N, Gupta V, Wong TT, Coote MA, Crowston JG. Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: A pilot study. Clin Experiment Ophthalmol 2012 Nov;40(8):773-779.
  24. Nilforushan N, Yadgari M, Kish SK, Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol 2012 Feb;153(2):352-335.
  25. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, et al. One-Year Outcomes of the da Vinci Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema. Ophthalmology 2012 Aug;119(8):1658-1665.
  26. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012 Mar;13(4):585-591.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.